PuraPharm Corporation Limited (HKG:1498)

Market Cap	189.63M
Revenue (ttm)	382.09M
Net Income (ttm)	-35.44M
Shares Out	395.05M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,000
Average Volume	99,438
Open	0.4900
Previous Close	0.4900
Day's Range	0.4800 - 0.4900
52-Week Range	0.4300 - 0.8500
Beta	-0.02
RSI	42.80
Earnings Date	May 28, 2025

About PuraPharm Corporation

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 479
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1498

Financial Performance

In 2024, PuraPharm Corporation's revenue was 382.09 million, a decrease of -6.09% compared to the previous year's 406.86 million. Losses were -35.44 million, -66.59% less than in 2023.